Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Poolbeg Pharma Ltd. ( (GB:POLB) ) just unveiled an announcement.
Poolbeg Pharma Ltd. has announced a retail offer via the BookBuild Platform to raise up to £100,000 through the issuance of new ordinary shares. This initiative is part of a larger fundraising effort totaling approximately £4.1 million, which includes a placing and subscription of new shares. The funds will support the company’s ongoing projects, including the Phase 2a trial of POLB 001, a potential breakthrough treatment for cancer immunotherapy-induced Cytokine Release Syndrome, and a proof of concept trial for an oral GLP-1 alternative targeting the obesity market. The retail offer is open to eligible UK shareholders and reflects the company’s commitment to its retail investor base.
More about Poolbeg Pharma Ltd.
Poolbeg Pharma Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative medicines to address unmet medical needs. The company operates in the biopharmaceutical industry with a market focus on creating treatments for conditions such as cancer immunotherapy-induced Cytokine Release Syndrome and obesity.
Average Trading Volume: 1,108,755
Technical Sentiment Signal: Sell
See more data about POLB stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue